Rapamycin can cause problems like high cholesterol, lung inflammation, and slower healing after surgery, which is why it's not used as a first-choice anti-rejection drug for kidney transplants.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Comprehensive safety profile of rapamycin
Systematic review and meta-analysis of all RCTs comparing rapamycin versus other immunosuppressants, analyzing adverse event rates including hyperlipidemia, pneumonitis, and wound healing complications
Causal evidence of side effect rates
Double-blind RCT comparing rapamycin versus tacrolimus in 500 renal transplant recipients, with systematic adverse event monitoring including lipid panels, pulmonary function tests, and surgical wound assessment over 12 months
Real-world adverse event rates
Prospective cohort of 1000 transplant patients on various immunosuppressant regimens, with standardized adverse event reporting and statistical adjustment for confounders
Documentation of specific adverse events
Case series documenting instances of rapamycin-associated pneumonitis, severe hyperlipidemia, or wound healing complications
Clinical perspective on side effect profile
Narrative review by transplant clinicians discussing rapamycin's side effect profile